80,762 Shares in Invesco BulletShares 2022 High Yield Corporate Bond ETF (BSJM) Acquired by Econ Financial Services Corp

Share on StockTwits

Econ Financial Services Corp purchased a new position in Invesco BulletShares 2022 High Yield Corporate Bond ETF (NYSEARCA:BSJM) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 80,762 shares of the company’s stock, valued at approximately $1,874,000. Invesco BulletShares 2022 High Yield Corporate Bond ETF makes up approximately 2.9% of Econ Financial Services Corp’s holdings, making the stock its 11th largest holding. Econ Financial Services Corp owned approximately 0.59% of Invesco BulletShares 2022 High Yield Corporate Bond ETF at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in BSJM. Atwood & Palmer Inc. purchased a new position in Invesco BulletShares 2022 High Yield Corporate Bond ETF in the 3rd quarter worth approximately $150,000. Winslow Evans & Crocker Inc. bought a new stake in shares of Invesco BulletShares 2022 High Yield Corporate Bond ETF in the 4th quarter worth approximately $230,000. Meridian Wealth Management LLC bought a new stake in shares of Invesco BulletShares 2022 High Yield Corporate Bond ETF in the 4th quarter worth approximately $258,000. Capital Investment Advisory Services LLC bought a new stake in shares of Invesco BulletShares 2022 High Yield Corporate Bond ETF in the 3rd quarter worth approximately $283,000. Finally, Sigma Planning Corp raised its holdings in Invesco BulletShares 2022 High Yield Corporate Bond ETF by 2.0% during the 4th quarter. Sigma Planning Corp now owns 23,100 shares of the company’s stock valued at $536,000 after buying an additional 455 shares during the last quarter.

Shares of BSJM opened at $24.39 on Tuesday. Invesco BulletShares 2022 High Yield Corporate Bond ETF has a 1 year low of $22.87 and a 1 year high of $24.86.

The firm also recently announced a monthly dividend, which was paid on Thursday, January 31st. Investors of record on Wednesday, January 23rd were issued a $0.109 dividend. This represents a $1.31 dividend on an annualized basis and a dividend yield of 5.36%. The ex-dividend date was Tuesday, January 22nd.

ILLEGAL ACTIVITY NOTICE: This piece was first reported by Zolmax and is the property of of Zolmax. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://zolmax.com/investing/80762-shares-in-invesco-bulletshares-2022-high-yield-corporate-bond-etf-bsjm-acquired-by-econ-financial-services-corp/2911161.html.

Featured Story: Federal Reserve

Want to see what other hedge funds are holding BSJM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Invesco BulletShares 2022 High Yield Corporate Bond ETF (NYSEARCA:BSJM).

Institutional Ownership by Quarter for Invesco BulletShares 2022 High Yield Corporate Bond ETF (NYSEARCA:BSJM)

Receive News & Ratings for Invesco BulletShares 2022 High Yield Corporate Bond ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invesco BulletShares 2022 High Yield Corporate Bond ETF and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

TreeHouse Foods Inc.  Shares Sold by Bank of New York Mellon Corp
TreeHouse Foods Inc. Shares Sold by Bank of New York Mellon Corp
Bank of New York Mellon Corp Has $35.41 Million Position in iShares Exponential Technologies ETF
Bank of New York Mellon Corp Has $35.41 Million Position in iShares Exponential Technologies ETF
GlycoMimetics  Raised to Buy at BidaskClub
GlycoMimetics Raised to Buy at BidaskClub
BidaskClub Downgrades Duluth  to Sell
BidaskClub Downgrades Duluth to Sell
Camtek  Raised to “Buy” at BidaskClub
Camtek Raised to “Buy” at BidaskClub
Reata Pharmaceuticals Inc  Given Average Rating of “Buy” by Brokerages
Reata Pharmaceuticals Inc Given Average Rating of “Buy” by Brokerages


 
© 2006-2019 Zolmax.